Intestinal Hyperechogenicity Confirmed by Evaluation of Gray Spectra
Launched by HOSPICES CIVILS DE LYON · Jun 18, 2025
Trial Information
Current as of June 28, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a way to improve how doctors diagnose a condition called intestinal hyperechogenicity, which means the baby's intestines look unusually bright on an ultrasound during pregnancy. This finding can sometimes be a sign of health issues like infections or genetic conditions, but it can also be a false alarm. Right now, doctors rely on their judgment to decide if the intestines look brighter than normal, which can be tricky and sometimes leads to unnecessary worry and extra tests for families. This study aims to use a more objective method to confirm whether the intestines are truly hyperechoic, hoping to reduce unnecessary referrals and help families feel more confident about their ultrasound results.
Pregnant women in their second or third trimester, whether expecting one baby or twins, who are having an ultrasound with a specific machine (Samsung Hera W10) at the hospital’s obstetrics department, may be eligible to join this study. Participants will have their ultrasound images reviewed using this new evaluation method. Being part of the study means you’ll help researchers find better ways to interpret ultrasound findings, which could make pregnancy care less stressful and more accurate in the future. If you’re interested, you should be able to understand the study details and agree to participate without any pressure.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women
- • in the second and third trimesters of pregnancy,
- • singletons or twins, diamniotics, adults,
- • undergoing screening or diagnostic ultrasound at obstetric and gynecology department,
- • on the Samsung Hera W10 ultrasound machine during the study
- • Patient able to understand the ins and outs of the study
- • Patient has been informed of the study and has expressed no objection to participating in it.
- Exclusion Criteria:
- • Minor patients
- • Persons deprived of their liberty by judicial or administrative decision
- • Persons under psychiatric care
- • Persons admitted to a health or social institution for purposes other than research
- • Adults under legal protection
About Hospices Civils De Lyon
Hospices Civils de Lyon (HCL) is a leading public health institution in France, dedicated to providing high-quality healthcare and advancing medical research. With a rich history dating back to the 18th century, HCL encompasses multiple hospitals and offers a diverse range of services across various medical specialties. The institution is committed to fostering innovative clinical trials that aim to enhance patient care and improve therapeutic outcomes. By collaborating with academic and industry partners, HCL plays a pivotal role in the development of new treatments and the advancement of medical knowledge, ensuring that research efforts are aligned with the highest ethical standards and patient safety protocols.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lyon, Rhone, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported